| Reeves DJ, Liu CY
Treatment of metastatic renal cell carcinoma. [JOURNAL ARTICLE]
Cancer Chemother Pharmacol 2009 Apr 3.
Abstract | Full Citation | Find Related Articles |
| Correale P, Tagliaferri P, Fioravanti A, et al.
Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial). [JOURNAL ARTICLE]
Clin Cancer Res 2008 Jul 1; 14(13):4192-4199.
Abstract | Full Citation |
| Davey RT, Pertel PE, Benson A, et al.
Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. [JOURNAL ARTICLE]
J Interferon Cytokine Res 2008 Feb; 28(2):89-100.
Abstract | Full Citation | Find Related Articles |
| Loppow D, Huland E, Heinzer H, et al.
Interleukin-2 inhalation Therapy Temporarily Induces Asthma-like Airway Inflammation. [Journal Article]
Eur J Med Res 2007 Nov 5; 12(11):556-62.
Abstract | Full Citation | Find Related Articles |
| Mealey RH, Littke MH, Leib SR, et al.
Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: Lack of correlation between in vitro activity and in vivo efficacy. [JOURNAL ARTICLE]
Vet Immunol Immunopathol 2007 Jul 25.
Abstract | Full Citation |
| Grandinetti CA, Goldspiel BR
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. [Journal Article]
Pharmacotherapy 2007 Aug; 27(8):1125-44.
Abstract | Full Citation |
| Margolin K, Atkins MB, Dutcher JP, et al.
Phase I Trial of BAY 50-4798, an Interleukin-2-Specific Agonist in Advanced Melanoma and Renal Cancer. [Journal Article]
Clin Cancer Res 2007 Jun 1; 13(11):3312-9.
Abstract | Full Citation | Find Related Articles |
| Steppan S, Kupfer K, Mayer A, et al.
Genome Wide Expression Profiling of Human Peripheral Blood Mononuclear Cells Stimulated With BAY 50-4798, a Novel T Cell Selective Interleukin-2 Analog. [JOURNAL ARTICLE]
J Immunother 2007 February/March; 30(2):150-168.
Abstract | Full Citation | Find Related Articles |
| Marie I, Joly P, Courville P, et al.
Pseudosystemic sclerosis as a complication of recombinant human interleukin 2 (aldesleukin) therapy. [Journal Article]
Br J Dermatol 2007 Jan; 156(1):182-3.
Full Citation | Find Related Articles |
| Khan KD, Emmanouilides C, Benson DM, et al.
A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma. [Journal Article]
Clin Cancer Res 2006 Dec 1; 12(23):7046-53.
Abstract | Full Citation | Find Related Articles |
  |
